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EVALUATING THE IMPACTS OF ANTIDEPRESSANT USE ON THE RISK OF 
DEMENTIA 
 
Dementia is a clinical syndrome caused by neurodegeneration or cerebrovascular 
injury1. Patients with dementia suffer from deterioration in memory, thinking, behavior 
and the ability to perform everyday activities2. Since there are no cures or disease-
modifying therapies for dementia3,4, there is much interest in identifying modifiable risk 
factors that may help prevent or slow the progression of cognitive decline4,5. Medications 
are a common focus of this type of research.6,7  
Importantly, according to a report from the Centers for Disease Control and 
Prevention (CDC), 19.1% of the population aged 60 and over report taking 
antidepressants during 2011-2014, and this number tends to increase8. However, 
antidepressant use among the elderly may be concerning because of the potentially 
harmful effects on cognition9-12. To assess the impacts of antidepressants on the risk of 
dementia, we conducted three consecutive projects.  
In the first project, a retrospective cohort study using Marginal Structural Cox 
Proportional Hazards regression model with Inverse Probability Weighting (IPW) was 
conducted to evaluate the average causal effects of different classes of antidepressant on 
the risk of dementia. Potential causal effects of selective serotonin reuptake inhibitors 
(SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), atypical anti-
depressants (AAs) and tri-cyclic antidepressants (TCAs) on the risk of dementia were 
observed at the 0.05 significance level. Multiple sensitivity analyses supported these 
findings.  
Unmeasured confounding is a threat to the validity of causal inference methods. 
In evaluating the effects of antidepressants, it is important to consider how common 
comorbidities of depression, such as sleep disorders, may affect both the exposure to anti-
depressants and the onset of cognitive impairment. In this dissertation, sleep apnea and 
rapid-eye-movement behavior disorder (RBD) were unmeasured and thus uncontrolled 
confounders for the association between antidepressant use and the risk of dementia. In 
the second project, a bias factor formula for two binary unmeasured confounders was 
derived in order to account for these variables. Monte Carlo analysis was implemented to 
estimate the distribution of the bias factor for each class of antidepressant. The effects of 




confounders were estimated. Sleep apnea and RBD attenuated the effect estimates for 
SSRI, SNRI and AA on the risk of dementia.  
In the third project, to account for potential time-varying confounding and 
observed time-varying treatment, a multi-state Markov chain with three transient states 
(normal cognition, mild cognitive impairment (MCI), and impaired but not MCI) and two 
absorbing states (dementia and death) was performed to estimate the probabilities of 
moving between finite and mutually exclusive cognitive state. This analysis also allowed 
participants to recover from mild impairments (i.e., mild cognitive impairment, impaired 
but not MCI) to normal cognition, and accounted for the competing risk of death prior to 
dementia. These findings supported the results of the main analysis in the first project. 
 
KEYWORDS: dementia, antidepressants, inverse probability weighting, unmeasured 
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CHAPTER ONE. INTRODUCTION 
1.1. Dementia 
Dementia, which includes Alzheimer’s disease, vascular dementia, Lewy body 
disease and frontotemporal dementia, is a clinical syndrome caused by neurodegeneration 
or cerebrovascular injury1.  Patients with dementia suffer from deterioration in memory, 
thinking, behavior and the ability to perform everyday activities2.  
In recent years, dementia has become an important public health topic worldwide 
due to its increasing prevalence in an aging society2. In the United States, the population 
age 65 and older is estimated to be 53 million in 201813, and this number is still 
increasing14. The number of Americans age 65 and older with Alzheimer’s or a related 
dementia in 2018 is estimated to be 5.5 million13. In other words, one in ten Americans 
age 65 and older has dementia.  
Dementia is known to be associated with extremely heavy burden on families and 
communities. It has been estimated that the yearly monetary cost per person attributable 
to dementia was between $41,689 and $56,290, depending on the method used to value 
informal care15. Therefore, the total monetary cost of dementia in 2010 has been 
estimated to be between $157 billion and $215 billion15.  
As there are no cures or disease-modifying therapies available for any disease that 
causes dementia3,4, there is major interest in identifying modifiable risk factors for 
dementia4,5, such as life style factors, medication use6,7, and comorbid health conditions16. 





1.2. Antidepressants   
Antidepressants are widely used among the elderly. According to a report from the 
Centers for Disease Control and Prevention (CDC), 19.1% of the population aged 60 and 
over reported taking antidepressants during 2011-2014, and this number tends to 
increase8. Besides treating depression, antidepressants have been used for treating other 
psychiatric disorders, such as anxiety, serious phobias, and post-trauma stress disorder17-
20. In some cases antidepressants can be used for treating long-term pain21. which is a 
common health condition among the elderly.  
However, antidepressant use among the elderly may be concerning because of the 
impacts of the underlying age-related pharmacokinetic and pharmacodynamic safety 
issues and potentially harmful drug-drug interactions on cognition22,23. For example, 
evidence has suggested that tri-cyclic antidepressants (TCAs) may increase the risk of 
cardiac arrhythmia and should be avoided for the elderly who are at high risk of 
cardiovascular diseases22,24, which is a risk factor for dementia. Another study suggests 
that combined use of antidepressants and NSAIDs is associated with an increased risk of 
intracranial hemorrhage within 30 days of initial combination25. More importantly, the 
conclusions regarding the effects of antidepressants on the risk of dementia are 
inconsistent26-28. Thus, the use of antidepressants among the geriatric population is a 
critical but under-investigated public health topic.  
 
1.3. Causal Inference for Observational Studies in Pharmacoepidemiology 
Ideally, the causal effects of treatments on outcomes should be investigated in a 




outcomes reflect the effects of the treatment rather than differences in participant 
characteristics29. However, randomized studies are not always feasible in real life, since 
some treatments cannot be randomized due to ethical considerations, and sometimes it is 
difficult to conduct head-to-head trials. If the subjects select their own treatments or the 
treatments are assigned to them by clinical professionals, the differences in outcomes 
may due to selection bias and confounding rather than the effects of the treatments29.  
For observational studies in pharmacoepidemiology, people may be interested in 
the average causal effects of a certain medication on a well-defined population. Hernán 
and Robins defined that an average causal effect of treatment A on outcome Y is present 
if 𝐸𝐸[𝑌𝑌𝑎𝑎=1] ≠ 𝐸𝐸[𝑌𝑌𝑎𝑎=0], where 𝑌𝑌𝑎𝑎 is the counterfactual outcome under a given treatment 
regimen A=a30. In other words, there is a causal effect of the treatment when the same 
population is observed under treatment and no treatment, and experiences a different 
outcome under each. In randomized trials, the treatment arms are assumed to be 
exchangeable (i.e., it doesn’t matter which group receives which treatment; the effects of 
the treatment should be the same in any group randomly assigned to that treatment), and 
thus causal effects are identifiable. Causal inference methods facilitate using 
observational data to determine the average causal effect by simulating randomized 
treatment assignment.  
Analytically the population average causal effects of a treatment can be estimated 
by Marginal Structural Models with Inverse Probability Weighting (IPW) estimator, 
given that the assumptions of conditional exchangeability, positivity, consistency, and 
correct model specification are satisfied30. IPW creates a pseudo-population in which the 




estimates as causal effects, we must assume there is no unmeasured confounding30. In 
such a pseudo-population, the average causal effects of the treatments on the outcomes 
can be estimated by regressing the outcome on the treatment using a marginal structural 
model, which is a conventional regression model weighted by IPW31.  
The traditional approach to adjust for confounding is to include confounders as 
covariates in a multiple regression model32. However, recent advances in epidemiological 
methods have shown that the traditional approach is often inadequate32,33. Greenland et al. 
suggested that the major drawback of the traditional approach to adjusting for 
confounders using statistical models is that they need many parametric assumptions that 
are not known to be correct or may be incorrect33. Therefore, in a high-dimensional study 
with many covariates and multi-group treatment, causal diagrams, such as Directed 
Acyclic Graphs (DAGs), can be used to identify a minimal sufficient set of adjustment 
variables that confound the effects of treatments on the outcomes by depicting a set of 
hypotheses about the causal process29.  
One of the key assumptions for causal inference in epidemiology is that there 
should not be any unmeasured confounding. Nevertheless, this assumption is often 
violated in observational studies. When unmeasured confounding exists but fails to be 
controlled for, the estimated treatment effects may be biased34. Monte Carlo Sensitivity 
Analysis could be used to adjust the data by estimating the sensitivity parameters for the 





1.4. About this Research  
The goal of this research is to investigate the causal effects of different classes of 
antidepressant medications on the risk of dementia using causal inference strategies. Data 
were obtained from the National Alzheimer’s Coordinating Center (NACC) Uniform 
Data Set (UDS). We hypothesize that antidepressant use among the elderly may increase 
the risk of dementia, and the impacts may be heterogeneous for different classes of 
antidepressant.  
In Chapter Two, a new user design retrospective cohort study was conducted to 
evaluate the causal effects of different classes of antidepressant on the risk of dementia 
by performing a Marginal Structural Cox Proportional Hazard Regression Model with an 
Inverse Probability Weighting estimator. Sensitivity analyses were conducted to assess 
the robustness of the main analysis results.  
In Chapter Three, the impacts of unmeasured confounders were assessed. 
Unmeasured confounding is a threat to the validity of causal inference methods. In 
evaluating the effects of anti-depressants, it is important to consider how common 
comorbidities of depression, such as sleep disorders, may affect both the exposure to anti-
depressants and the onset of cognitive impairment. In this dissertation, sleep apnea and 
rapid-eye-movement behavior disorder (RBD) were identified as confounders by our 
hypothesized causal model but were unmeasured and thus uncontrolled confounders for 
the association between antidepressant use and the risk of dementia. A bias factor 
formula for two binary unmeasured confounders was derived in order to account for these 




factor for each class of antidepressant. The effects of antidepressants on the risk of 
dementia adjusted for both measured and unmeasured confounders were estimated.  
In Chapter Four, a multi-state Markov chain with three transient states (normal 
cognition, impaired but not MCI, and MCI) and two absorbing states (dementia and death 
prior to dementia) was built to account for changes in treatment over time and time-
varying covariates. A series of multinomial logistic regression models were constructed 
to model the log-odds of transitions between any two transient states and transitions 
between a transient state and an absorbing state. The long-run behavior of the chain was 
also evaluated. 
Finally, a conclusion of this research and discussion of directions for future 







CHAPTER TWO. THE EFFECTS OF ANTIDEPRESSANT USE ON THE RISK OF 
DEMENTIA: A RETROSPECTIVE COHORT STUDY 
2.1. Introduction  
Dementia has become a significant public health issue worldwide in recent years2. 
Patients with dementia suffer from deterioration in memory, thinking, behavior and the 
ability to perform everyday activities1. The prevalence of age-related dementia in the 
United States in 2010 is estimated to be 14.7% for those aged 70 or older36. Since there 
are no cures or disease-modifying therapies for dementia3,4, there is much interest in 
identifying modifiable risk factors that may help prevent or slow the progression of 
cognitive decline4,5. Medications are a common focus of this type of research6,7, and 
antidepressant use is a possible modifiable risk factor in the geriatric population. 
Importantly, according to a report from the Centers for Disease Control and Prevention 
(CDC), 19.1% of the population aged 60 and over report taking antidepressants during 
2011-20148. In other words, one fifths of this population were using antidepressants.  
Antidepressants can be identified based on their mechanisms of action: selective 
serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors 
(SNRIs), tri-cyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and 
atypical antidepressants (AAs). All these antidepressants work to increase the levels of 
one or more of the neurotransmitters in the patient’s body—serotonin, norepinephrine, or 
dopamine—but different classes of drugs achieve this goal very differently37.  
SSRIs help to reduce symptoms of depression through increasing the amount of 
serotonin by blocking the re-absorption of serotonin in the brain38. SNRIs differ from 




norepinephrine39. TCAs were one of the earliest antidepressants developed, and they will 
also increase the levels of serotonin and norepinephrine40. However, TCAs lead to more 
side effects compared to SSRIs and SNRIs, because TCAs will simultaneously impact 
other chemicals in the human brain41. MAOIs function by preventing monoamine oxidase, 
an enzyme, from removing serotonin, norepinephrine, and dopamine so that the levels of 
these neurotransmitters are maintained in brain42. MAOI users also report more side 
effects compared to SSRI or SNRI users due to MAOI’s impact on other 
neurotransmitters and the digestive system43. AAs work through novel mechanisms of 
action, but in general they also elevate the levels of serotonin, norepinephrine, or 
dopamine44,45.  
According to guidelines of the National Health Services (NHS) in England46, 
when antidepressant therapy is necessary, SSRIs are normally considered as the first-line 
treatment; other classes of antidepressants are generally used as second-line or third-line 
treatment. A combination of two different classes should be initiated by specialists only. 
However, it should be noted that the selection of a particular medication for a particular 
patient depends on a variety of factors, such as the avoidance of specific side effects and 
the presence of comorbidities, so there is not one antidepressant medication that is clearly 
more effective than another at the population level47.  
No strong conclusions can be made from current studies focusing on the 
relationship between antidepressant use and dementia. First, different antidepressants 
work via different mechanisms of action, and there are very few studies comparing the 
potential heterogeneous effects of antidepressant classes on the risk of dementia among 




trials, thus the effects of antidepressants on the elderly in settings where causal inference 
is straightforward remain under-investigated50. Finally, existing studies investigating the 
effects of antidepressants made inconsistent conclusions. Some in vivo studies showed 
that chronic SSRI treatment reduces amyloid-β accumulation, which is a marker for 
Alzheimer’s disease, in mice, and this benefit also appears to be true in humans26-28. 
However, a randomized, placebo-controlled, double-blind, parallel group clinical trial 
study showed that fluoxetine, a commonly used SSRI, is associated with worsening 
cognitive functions51. A cross-over clinical study focusing on the effect of SNRI on 
memory and mental processing speed concluded that SNRIs may improve memory, 
mental processing speed and motor performance52, but a large cohort study suggests that 
SNRI use is associated with increased risk for dementia51. Some AAs, such as 
amitriptyline, dothiepin, mianserin, and trazodone, may impair attention and ability to 
concentrate53. Yet, another study recommends that AAs are preferable in the elderly 
patients because use of risperidone, a type of AA, in Alzheimer’s disease subjects did not 
result in a significant reduction in MMSE score over a 12-week period compared with 
placebo group, while a lower rate of adverse events was observed54. With inconsistent 
information, it is difficult to draw any conclusions regarding the impacts of 
antidepressants on the risk of dementia.  
To summarize previous studies on human subjects investigating the relationship 
between antidepressant use and dementia, both randomized trials and observational 
studies have limitations. Most studies investigating this topic are preclinical studies with 
animal subjects. In randomized clinical trials, the elderly were usually excluded from the 




population. On the other hand, the existing observational studies suffer from 
methodologic flaws such as confounding by indication and unmeasured confounders. 
Additionally, none of the previous studies investigated the causal effects.  
Hence, the goal of this study was to evaluate the causal effects of different classes 
of antidepressant medications on the risk of dementia by conducting a retrospective 
cohort study using the National Alzheimer’s Coordinating Center’s (NACC) Uniform 
Data Set (UDS). This study primarily focused on SSRIs, SNRIs, AAs and TCAs. MAOIs 
were not included due to small numbers who reported taking these drugs.  
 
2.2. Methods 
2.2.1. Data Source and Study Population  
This study used the NACC’s Uniform Data Set (UDS), which is a prospective and 
longitudinal clinical evaluation database48. The data are collected annually from 
Alzheimer’s Disease Centers (ADCs) funded by the National Institute on Aging (NIA)55. 
Since September 2005, all participants in ADC studies have been followed by a standard 
data collection protocol (i.e., the UDS). The UDS was collected by trained clinicians and 
clinical practitioners from participants and their co-participants during in-person office 
visits, home visits and telephone calls. Although the focus of the ADCs is Alzheimer’s 
disease, the UDS also enrolls subjects with a wide range of other related disorders, such 
as vascular dementia, Lewy body dementia and frontotemporal lobar degeneration. 





Generally speaking, the UDS subjects are referral-based or volunteer case series56, 
thus they are unlikely to be a representative sample of the U.S. population. As of 
September 2018, among all 38,836 UDS subjects, 35.1% carried a diagnosis of normal 
cognition, 17.2% were MCI, 4.3% were impaired but not MCI, and 43.4% were 
diagnosed with any form of dementia. As a comparison, only 8.8% of the U.S. population 
aged 65 and above was diagnosed with dementia in 201257. In addition, the UDS 
population consists of slightly higher percentage of females (57.1%), which is consistent 
with the general population of older adults (56.9%)58. However, the percentage of 
subjects with higher education (72.3% had some college or more) is much higher than the 
general population of older adults (49.7% of 65 and older had some college or more)59.  
 
2.2.2. Study Design  
A new-user design retrospective cohort study matched on the index visit was 
conducted using the NACC UDS from September 2005 to September 2018 (see Figure 
2.1). Besides the exclusion criteria applied by each ADC, this study further excluded 
subjects who were:  
1) prevalent dementia patients at the index visit;  
2) prevalent antidepressant users defined based on reported use at the initial UDS 
visit;  
3) MAOI users or combination users;  
4) younger than 65-years-old at the at the initial UDS visit;  




In this study, the index visit is defined as the UDS visit when a subject first 
reported initiation of an antidepressant. The baseline visit is defined as the UDS visit 
prior to the index visit. The initial visit is the first UDS visit. Due to the sparseness of 
MAOI users, subjects who reported using this type of antidepressants were excluded 
from the study. Participants who reported using more than one type of antidepressant 
were also excluded due to their heterogeneity. Hence, we make comparison among non-
users, SSRI users, SNRI users, TCA users and AA users.  
 
2.2.3. Treatment and comparison groups 
Among the eligible subjects, those who ever initiated one or more of the 
treatments prior to a relevant event (dementia, death prior to dementia, or the last UDS 
visit) were identified. Each subject in the treatment groups was randomly matched with 
three nonusers who had not started any antidepressant at that same UDS visit to avoid the 
immortal time bias60. Matched non-users may report antidepressant use at a later UDS 
visit, but they will not contribute follow-up time to the treated cohort. This is similar to 
an intent-to-treat design.  
For example, participant A initiates a certain antidepressant medication at the 
second UDS visit (Figure 2.2). Three participants (C, G and I) who have not initiated any 
antidepressant at their second UDS visit will be randomly selected as control subjects. 
The second UDS visit is the index visit for all four participants. The visit prior to the 
index-visit, which is first visit in this example, is the baseline visit for these four subjects. 
Although participant C starts treatment at the fifth visit, this patient will stay in the 





2.2.4. Antidepressant Measurement  
At each UDS visit, subjects were asked about their antidepressant use within the 
past two weeks before the current visit. Four classes of antidepressants, SSRIs, SNRIs, 
TCAs, and AAs were identified based on subjects’ self-reported medication use at the 
index visit. For the purpose of this study, prevalent antidepressant users were removed, 
and incident antidepressant users and non-users were included.  
Prevalent users were defined as active users of any type of antidepressant 
identified in this study at the initial UDS visit. Incident antidepressant users were defined 
as new users of any type of antidepressant identified in this study during the follow-up. 
Non-users were defined as participants who never initiated any antidepressant identified 
in this study during the follow-up. If a participant reported using two or more classes of 
antidepressant at one UDS visit, this participant was defined as combination users. As 
mentioned earlier, combination users were not of the primary interest in this study, five 
groups are compared: SSRI group, SNRI group, AA group, TCA group and the non-users. 
Table 2.1 summarizes the antidepressant classification and the generic drug names in 
each class.  
 
2.2.5. Dementia Status Assessment  
Clinicians assessed the cognitive and behavioral status of participants at each 
UDS visit. Cognitive status is classified into four levels in the UDS: normal cognition, 
MCI, impaired but not MCI, and dementia. Dementia incidence is defined as the first 




cognitive or behavioral symptoms should be met. Specially, to be diagnosed with 
dementia, the cognitive impairment should (taken from the UDS coding guide book)61:  
1) interfere with ability to function as before at work or at usual activities;  
2) represent a decline from previous levels of functioning;  
3) not be explained by delirium or major psychiatric disorder;  
4) include cognitive impairment detected and diagnosed through a combination of 
history-taking and objective cognitive assessment (bedside or neuropsychological 
testing).  
And, the participant must also show impairment in one or more of the following domains:  
1) ability to acquire and remember new information;  
2) reasoning and handling of complex tasks, poor judgment;  
3) visuospatial abilities;  
4) language functions;  
5) changes in personality, behavior, or comportment.  
 
2.2.6. Death Assessment  
Mortality information is obtained from the NACC Milestone Form62. Year and 
month of death are obtained for subjects who are known to be deceased. Day of death 
was set to be 15th since this information was not available in the Milestone Form, and we 
assumed deaths would be distributed randomly and uniformly during the month (thus, the 
mean day of death for all participants who died in a particular month would be the middle 
of the month). If a participant died before developing any form of dementia, then this 




diagnosis are not of interest in this study since our focus was on risk of dementia, with 
death as a competing event. 
 
2.2.7. Administrative Censoring  
According to the protocol of the UDS, participants may be censored because 
participants or co-participants asked to withdraw from the study, or participants could 
also be withdrawn due to an ADC decision or protocol62. For the purpose of this study, if 
subjects never developed dementia or died, they were right-censored at the last contact. 
This includes both participants who withdrew and participants still under follow-up. 
 
2.2.8. Baseline Covariates Assessment  
A Directed Acyclic Graph (DAG) was constructed via DAGitty.net63 to identify 
the minimal sufficient adjustment set based on the hypothesized causal association 
between antidepressant use and dementia (Figure 2.3). Variables were included in the 
DAG regardless of their availability in the NACC UDS data. Demographic variables 
included age, sex, race and education. Lifestyle variables were smoking and alcohol 
abuse. Comorbidities were traumatic brain injury (TBI), Parkinson’s disease, 
hypertension, type 2 diabetes, high cholesterol, stroke, cardiovascular disease (CVD), 
depression status, any psychiatric conditions except for depression (i.e. post-traumatic 
stress disorder, bipolar disorder, schizophrenia or anxiety), standard CDR sum of boxes 
and cognitive status. History of medication use variables were NSAIDs, opioid 




allele status. Prior antidepressant use was not considered in this graph because prevalent 
antidepressant users were excluded from the study.  
The minimal sufficient adjustment set included the baseline values of age, pain 
medication use (as proxy for chronic pain), sleep disorders, depression status, GDS score, 
any other psychiatric conditions except for depression (i.e., post-traumatic stress disorder, 
bipolar, schizophrenia, anxiety, obsessive-compulsive disorder or developmental 
neuropsychiatric disorder), standard CDR sum of boxes and cognitive status.   
 
2.2.9. Statistical Analysis  
2.2.9.1. Descriptive analysis  
Subject characteristics at baseline stratified by the treatment groups were 
summarized for the original cohort and the pseudo-cohort (the pseudo-cohort is defined 
and described below). Means and standard deviations were reported for normally-
distributed continuous variables. Median and interquartile range were reported for non-
normally-distributed variables. Frequencies and percentages were reported for categorical 
variables.  
 
2.2.9.2. Main analysis   
Kaplan-Meier curves by treatment groups were plotted to visualize the 
distribution of dementia-free-survival-times across the five groups. Log-Rank tests 
between each treatment group and the control group were performed to quantitively 




Cox Proportional Hazard Regression with IPW was performed to evaluate the 
effects of different antidepressant classes on the risk of dementia. To perform this 
analysis, it is necessary to 1) build propensity score models to obtain the weights for 
balancing the subject baseline characteristics; 2) apply weights to the original cohort to 
construct a “weighted and balanced” pseudo-cohort; 3) evaluate the balance of the 
pseudo-cohort; and 4) construct a weighted Cox Proportional Hazards regression with 
antidepressant treatment status as the only predictor in the model. The model in step 4 is 
called a marginal structural model and estimates the marginal causal effects of 
antidepressants on the risk of developing dementia. Standardized Mean Differences 
(SMDs) between each treatment group and the control group were calculated to assess 
the effectiveness of the inverse probability weighting in balancing the baseline 
characteristics of the treated and untreated groups in the pseudo-cohort.  
Two propensity score models were built to obtain two sets of weights respectively: 
weights for balancing the prognostic factors of receiving different classes of 
antidepressant (i.e. inverse probability of treatment weights), and the weights for 
accounting for censoring (i.e. inverse probability of censoring weights).  
The propensity score model of treatment predicted a participant’s probability of 
receiving a particular treatment given the observed participant factors via a multinomial 
logistic regression with the five treatment groups as the outcome. The model produces 
probabilities of receiving each of the five treatments, which sum to 1.00, for each 
participant. Participants are then weighted by the inverse of the predicted probability of 
the treatment that they actually received. Stabilized weights were calculated by 




by the observed marginal probabilities of receiving this treatment64. Selection of 
covariates included was based on the minimal sufficient adjustment set from the DAG 
(Figure 2.3), which were the baseline values of age, chronic pain, sleep disorders, 
depression status, GDS score, any other psychiatric conditions except for depression, and 
cognitive status. Chronic pain is not directly measured in the UDS, thus NSAIDs or 
opioid medication use was used as a surrogate for chronic pain. Additionally, sleep 
disorder variables were not included in the model due to the fact of heavy missingness 
(sleep disorder data have been collected in the UDS only since March 2015).  
The propensity score model of censoring predicts the probability of being 
censored given the observed covariate values at baseline via a binary logistic regression 
with censoring as the outcome. Covariates adjusted in this model are baseline 
characteristics that we believed to be associated with being censored. Specifically, sex, 
age, years of education, race, smoking, alcohol abuse, history of TBI, Parkinson’s disease, 
hypertension, diabetes, high cholesterol, stroke, cardiovascular disease, chronic pain, 
depression status, other psychiatric conditions and cognitive status were included in the 
model. Stabilized weights were calculated by multiplying the inverse of the predicted 
probabilities of being censored given the observed covariates values by the observed 
marginal probabilities of being censored64.  
The joint weights for balancing the overall subject baseline characteristic 
distributions are computed by multiplying the stabilized weights for treatment and the 
stabilized weights for censoring65. The joint weights are applied to the original cohort to 
obtain a pseudo-cohort, or “weighted cohort”. In the weighted cohort, the overall 




Such balance of measured baseline characteristics mimics a randomized clinical trial, in 
which the probabilities of being assigned to any treatment arm are independent of 
confounding variables, and the probabilities of being censored are independent as well. 
The use of both weights jointly adjusts for both confounding at baseline and selection 
bias during follow-up. Standardized mean differences between each treatment group and 
the control group were calculated to assess the effectiveness of weighting.  
A weighted Cox Proportional Hazards regression with antidepressant treatment 
status as the only predictor in the model was performed to estimate the marginal effects 
of antidepressants on the risk of developing dementia. The proportional hazards 
assumption was checked by incorporating an interaction term of treatment by time in the 
model.  
 
2.2.9.3. Sensitivity Analyses  
Three sensitivity analyses were conducted to assess the robustness of the main 
analysis results. Sensitivity Analysis One used a restricted cohort with participants who 
had not reported a diagnosis of depression or any other psychiatric conditions at the 
baseline visit. All other analysis procedures remained the same as the main analysis. The 
aim of Sensitivity Analysis One was to determine if the estimates in the main analysis 
were impacted by confounding by indication, where the observed effect of the 
medications is actually due to the pre-existing psychiatric conditions.  
Sensitivity Analysis Two further includes ApoE ε4 status in the IPW model in 
addition to the covariates adjusted in the IPW model in the main analysis. All other 




ApoE ε4 status is related to antidepressant use. However, ApoE ε4 carriers are at greater 
risk of developing Alzheimer’s disease compared with others66, and it has been 
hypothesized that depression may occur during the preclinical phase of the disease67. The 
purpose of the Sensitivity Analysis Two was to determine if ApoE ε4 status would 
influence the estimates even though it was not hypothesized to be a confounder in the 
pathway between antidepressant use and dementia.  
Sensitivity Analysis Three used time-varying treatment instead of the fixed 
treatment at the index visit. Changes between any treatment groups, including change 
from one class to another, users to non-users or vice versa, were allowed. Participants’ 
baseline characteristics were balanced using the IPW. A Cox Proportional Hazards 
regression with treatment as the time-varying covariate in the model was performed. The 
aim of Sensitivity Analysis Three was to determine if the estimates in the main analysis 
were impacted by the potential treatment regimen changes in later UDS visits.  
 
2.3. Results  
2.3.1. Descriptive Summaries 
Participant characteristics at study baseline (i.e., the visit prior to the index visit) 
are summarized in Table 2.2. Briefly, approximately 75% of the included subjects were 
antidepressant-naïve, 14.4% of the subjects initiated SSRI use, 2.3% of the subjects 
initiated SNRI use, 5.4% of the subjects initiated AA use, and 2.9% of the subjects 
initiated TCA use. In total 645 out of 4302 participants (15.0%) were diagnosed with 
incident dementia during follow-up. Treatment groups had higher proportions of 




SNRIs, AAs and TCAs respectively) compared to the control group (12.3%). SSRI, SNRI 
and AA users were estimated to have shorter median dementia-free-survival-times (2.7, 
2.2, and 3.0 years for SSRIs, SNRIs, and AAs respectively) compared to the non-user 
group (3.1 years). However, the diagnoses may not occur on the visit date thus the 
dementia-free-survival times may be overestimated.  
Mean baseline ages across the five groups were similar; the SNRI group had the 
lowest mean baseline age and the AA group had the highest (Table 2.2). Regarding the 
use of pain medications, SNRI users, AA users, and TCA users had higher proportions of 
subjects who reported using NSAIDs or opioid medications compared to controls and 
SSRI users. Psychiatric disorders, including depression and any other psychiatric 
conditions, were in general more common among the antidepressant users (SSRIs, SNRIs, 
AAs, and TCAs) than among the controls. Antidepressant users also tended to have 
higher burden of depressive symptoms compared to the controls, based on the Geriatric 
Depression Scale (Table 2.2). Even though there is not much difference regarding the 
standard CDR sum of boxed across the groups, the control group had more participants 
with normal cognition at baseline, while the antidepressant groups had more participants 
with MCI at baseline. Hence, the distributions of the risk factors for dementia are not 
balanced across groups. In other words, the treatment groups and control group are not 
exchangeable.  
Table 2.3 summarizes the baseline characteristics for the weighted cohort 
(pseudo-cohort). In the weighted cohort, the risk factors for dementia at baseline were 
distributed with good balance across the five groups in general. The SMDs of the 




observed cohort are larger than 0.1 in general, indicating that the baseline risk factor 
distributions are not comparable between each antidepressant group and the control group. 
In the weighted cohort, the SMDs between each antidepressant group and the control 
group are significantly reduced, suggesting balance across groups (Figure 2.4).  
 
2.3.2. Main Analysis  
Kaplan-Meier curves (Figure 2.5) and the Log-Rank test results showed that the 
users of any antidepressant had significantly shorter median dementia-free-survival-times 
compared to the control group (P-values<.0001). Among the antidepressant classes, SSRI 
users had significantly shorter dementia-free-times compared to other antidepressant 
users (P-values <.0001). There were no significant pair-wise differences among SNRI 
users, AA users, and TCA users.  
A weighted Cox Proportional Hazards regression model with antidepressant 
treatment as the only predictor in the model was performed. Subjects who reported using 
SSRIs, SNRIs, AAs, and TCAs at the index visit were estimated to have 2.04 (1.69-2.48), 
2.10 (1.33, 3.31), 1.46 (1.05, 2.03) and 1.58 (1.04, 2.41) times the hazard of developing 
dementia compared to subjects who did not report using any antidepressants at the index 
visit, respectively. In other words, antidepressant users progressed to dementia more 
quickly compared to the non-users. All estimated effects were significant at the 0.05 
significance level. There is no evidence that the proportional hazards assumption was 





2.3.3. Sensitivity Analyses 
The point estimates for hazard ratio obtained from Sensitivity Analysis One, 
where only participants who did not report a psychiatric diagnosis were included, 
remained consistent with the main analysis in general, indicating that the estimates were 
not sensitive to confounding by indication. In Sensitivity Analysis Two, where ApoE ε4 
status was included in the propensity score model, the point estimates of a hazard ratios 
remain consistent with the estimates in the Main Analysis. However, the estimated 
confidence intervals in Sensitivity Analysis One and Sensitivity Analysis Two for AA 
users and TCA users contains the null hazard ratio one. This was likely due at least in 
part to the reduced sample size, because ApoE ε4 genotyping was unavailable for 7.2% 
of participants. Sensitivity Analysis Three, which allowed treatment status to vary over 
time, also generated consistent estimated hazard ratios compared to estimates in the Main 
Analysis.  
 
2.4. Discussion  
In this study, we found that all antidepressant classes investigated increased the 
hazard for dementia. SNRIs increase the levels of serotonin and norepinephrine in brain, 
and both chemicals have been reported to enhance cognitive functions68,69, but in this 
analysis SNRI use was associated with the shortest dementia-free-time. A possible 
explanation is that SNRIs may increase the risk of dementia via hypertension as a 
mediator. It is known that SNRIs may increase users’ blood pressure64,70, and 
hypertension has been reported as a risk factor for vascular dementia and Alzheimer’s 




hypertension at baseline (64.7% for SNRI users versus 61.1% for SSRI users, 62.0% for 
AA users, 59.4% for TCA users and 58.1% for controls). Hence, the SNRI users may 
have higher risk of dementia at least in part because of the increased high blood pressure. 
Alternatively, if SNRI treatment is related to the presence of preclinical 
neurodegenerative disease (i.e., it is a result of reverse causality), this could explain the 
association.  
The underlying biological mechanism for increased dementia risk in SSRI users 
remains unclear22. A possible explanation is that there might be a pathway between 
SSRIs and dementia through zinc. An animal study has found upregulation of the GPR39 
Zn2+-sensing receptor protein level after SSRI treatment72. Imbalance in zinc levels may 
lead to neurofibrillary tangles, which is believed to be a marker of Alzheimer’s disease 
and cognitive impairment73, but further research on human subjects is still needed in 
answering this question. Again, if SSRI treatment is related to the presence of preclinical 
neurodegenerative disease, this could also explain the association.  
In clinical practice, AAs are often prescribed for treating other health conditions 
besides depression. For example, trazodone is the second most commonly prescribed 
medication for treating insomnia74, and insomnia is a risk factor for dementia75. The link 
between AA use and dementia may be through unrecognized and unmeasured 
confounders like insomnia. TCAs are usually not prescribed as the first-line treatment for 
the elderly because TCAs may cause more side effects compared to other agents76. These 
side effects include blurred vision and drop in blood pressure when moving from sitting 




SSRIs, if treatment is related to the presence of preclinical neurodegenerative disease, 
this could explain the association.  
There are several strengths of this study. First, successful IPW in this study 
reduces selection bias at baseline by creating a balanced pseudo-cohort, in which the 
probability of receiving a certain antidepressant treatment is independent of the observed 
baseline prognostic factors. Hence, the average causal effects of each antidepressant class 
on the risk of dementia were estimated in this study. While we do not assume that all the 
conditions for causal inference based on observational data were met fully in this study, 
we think it is valuable to carefully consider the hypothesized causal model and to be 
transparent about the assumptions we made. Second, all potential confounders would be 
included in the propensity score model in a conventional approach, however this 
approach has been proved inadequate32,33. In this study, a DAG was built to identify the 
minimal sufficient set for confounder adjustment. The DAG reduces the number of 
parametric assumptions needed for this study compared to the number of parametric 
assumptions needed in a conventional approach.  
This study has some limitations. First, we did not control for all sources of 
confounding. For example, we were not able to control well for confounding by 
depression severity. Also, due to the inconsistent data collection protocols over time, 
some important variables, like those documenting sleep disorders, were only collected for 
UDS version 3, which was implemented in 2015, and are not available for UDS visits 
prior to this new implementation. This leads to missingness on some major potential 
confounders, such as sleep apnea history, REM sleep behavior disorder history, and 




regardless of any treatment regimen change in later visits. Change of antidepressant 
treatment may indicate depression progression or medication resistance, but these issues 
were largely ignored in this study. However, the sensitivity analysis that allowed 
participants to change medications did not provide evidence that our main results were 
due these factors. Another limitation is that the measurement of treatment is not ideal. For 
example misclassification of treatment is possible given the long gap between two visits; 
also there is no information about dosage or length of treatment. Drug-drug interaction 
was not investigated. It is common that the elderly may simultaneously take multiple 
medications given the complex health conditions associated with aging, but the 
possibility of drug-drug interaction was not considered for this study. We also cannot 
exclude the possibility of reverse causality78, where preclinical neurodegenerative disease 
causes depression, which causes antidepressant initiation, which induces the association 
between antidepressant use and dementia. Studies with decades of follow-up, where 
incident cases that arise in the first pre-determined number of years of treatment are 
excluded, are needed to test the reverse causality hypothesis79.  Finally, we could not 
examine the effects of individual antidepressant medications or conduct proper 
comparative effective research due to sample size limitations. 
 
2.5. Conclusion  
In this study, Cox Proportional Hazard Regression with Inverse Probability 
Weighting was performed to evaluate the effects of different antidepressant classes on the 
risk of dementia. Significant causal effects of SSRIs, SNRIs, AAs and TCAs on the risk 




not sensitive to confounding by indication of psychiatric disorders, genetic risk due to 
ApoE ε4, or treatment regime switches in later visits.  
All medications carry some risk of side effects that must be weighed against the 
therapeutic benefit of the medications. For depressed elderly, antidepressant therapies are 
important for maintaining quality of life. The question of whether their use causes an 
increased risk of dementia causing diseases remains open, and the answer is important. 
However, it is clearer is that the use of these antidepressant classes appears to hasten the 




Table 2.1. Antidepressant Classifications and Generic Drug Names  
Classification Generic Drug Name 
SSRI1 fluoxetine, paroxetine, sertraline, citalopram, escitalopram, 
vilazodone 
SNRI2 duloxetine, venlafaxine, desvenlafaxine, levomilnacipran 
AA3 trazadone, mirtazapine, vortioxetine, bupropion, nefazodone 
TCA4 imipramine, nortriptyline, amitriptyline, doxepin, desipramine, 
amoxapine, protriptyline, trimipramine 
1Selective serotonin reuptake inhibitors 
2Serotonin and norepinephrine reuptake inhibitors 
3Atypical antidepressants 




Table 2.2. Subject Characteristics at Baseline for the Observed Cohort  
 None SSRI1 SNRI2 AA3 TCA4 
N  3225 (75.0) 619 (14.4) 99 (2.3) 234 (5.4) 125 (2.9) 
Age (year) 77.5 ± 7.3 76.1 ± 7.2 74.8 ± 6.9 77.1 ± 7.9 76.7 ± 8.2 
Pain meds5 1430 (44.3) 279 (45.5) 51 (51.5) 123 (52.6) 68 (54.4)  
Depression  410 (12.7) 274 (44.3) 51 (51.5) 90 (38.6) 35 (28.2)  
GDS6 0 (0, 1) 1 (0, 3) 2 (0, 4) 1 (0, 2) 1 (0, 2)  
Psychiatric7 110 (3.4) 60 (9.7)  6 (6.1)  19 (8.1)  4 (3.2)  
CDR8 0 (0, 0.5)  0.5 (0, 1)  0 (0, 1)  0 (0, 0.5)  0 (0.5)  
Cognition 
     Normal  
     Impaired9 
     MCI10 
 
2442 (75.7)  
148 (4.6)  
635 (19.7)  
 
336 (54.3)  
67 (10.8)  
216 (34.9)  
 




152 (65.0)  
11 (4.7)  
71 (30.3)  
 
91 (72.8)  
3 (2.4)  
31 (24.8)  
ApoE ε4 +   871 (29.0) 189 (33.4) 32 (37.2) 71 (31.6) 31 (27.2) 
Dementia incidence  396 (12.3)  165 (26.7) 18 (18.2) 45 (19.2) 21 (16.8)  
Time to dementia (year) 3.1 (1.9, 5.5)  2.7 (1.2, 4.9) 2.2 (1.2, 4.8) 3.0 (1.6, 4.8) 3.3 (1.4, 5.2) 
Note: Mean ± S.D. are reported for normally-distributed continuous variables. Median (Q1, Q3) are reported for non-normally-
distributed variables. Frequency (%) are reported for categorical variables. 
1Selective serotonin reuptake inhibitors  
2Serotonin and norepinephrine reuptake inhibitors  
3Atypical antidepressants  
4Tri-cyclic antidepressants  
5NSAIDs or opioid medications  
6Total Geriatric Depression Scale Score  
7Any other psychiatric conditions except for depression, including post-traumatic stress disorder, bipolar, schizophrenia, anxiety, 
obsessive-compulsive disorder or developmental neuropsychiatric disorder 
8CDR sum of boxes  
9Impaired but not MCI  





Table 2.3. Subject Characteristics at Baseline for the Weighted Cohort  
 None SSRI1 SNRI2 AA3 TCA4 
N  3200 651 100 240 127 
Age (year) 77.4 ± 7.3 77.6 ± 7.6  76.9 ± 7.1  77.6 ± 7.8  77.6 ± 8.1  
Pain meds5 1479 (45.9) 305 (47.7)  53 (51.6)  108 (44.8)  55 (43.3)  
Depression  657 (20.5)  146 (22.5)  24 (24.3)  54 (22.5)  24 (19.2)  
GDS6 1 (0, 2)  1 (0, 2) 1 (0, 2) 1 (0, 2) 1 (0, 2) 
Psychiatric7 162 (5.0)  40 (6.2)  5 (5.1)  15 (6.0)  4 (3.2)  
CDR8 0 (0, 0.5)  0 (0, 0.5)  0 (0, 0.5)  0 (0, 0.5)  0 (0, 0.5)  
Cognition 
     Normal  
     Impaired9 
     MCI10  
 
2254 (70.4) 
188 (5.9)  
758 (23.7)  
 
464 (71.3)  
39 (6.0)  
148 (22.7)  
 
74 (73.6)  
6 (6.3)  
20 (20.1)  
 
167 (69.4)  
14 (5.7)  
60 (24.9)  
 
94 (73.7)  
6 (4.6)  
28 (21.7)  
Note: Mean ± S.D. are reported for normally-distributed continuous variables. Median (Q1, Q3) are reported for non-normally-
distributed variables. Frequency (%) are reported for categorical variables. 
1Selective serotonin reuptake inhibitors  
2Serotonin and norepinephrine reuptake inhibitors  
3Atypical antidepressants  
4Tri-cyclic antidepressants  
5NSAIDs or opioid medications  
6Total Geriatric Depression Scale Score  
7Any psychiatric conditions except for depression, including post-traumatic stress disorder, bipolar, schizophrenia, anxiety, obsessive-
compulsive disorder or developmental neuropsychiatric disorder  
8Standard CDR sum of boxes  
9Impaired but not MCI  





Table 2.4. Hazard Ratios (95% CIs) for Main Analysis and Sensitivity Analyses 
 Main Analysis Sensitivity Analysis One1 Sensitivity Analysis Two2 Sensitivity Analysis Three3 
SSRI4  2.04 (1.69, 2.48) 1.93 (1.49, 2.51)  1.82 (1.48, 2.23) 2.78 (2.26, 3.42)  
SNRI5 2.10 (1.33, 3.31) 2.56 (1.37, 4.75)  2.24 (1.39, 3.60) 3.01 (1.95, 4.64)  
AA6 1.46 (1.05, 2.03) 1.42 (0.89, 2.25)  1.36 (0.95, 1.93) 1.80 (1.23, 2.64)  
TCA7 1.58 (1.04, 2.41) 1.53 (0.92, 2.54)  1.12 (0.68, 1.86) 1.67 (0.90, 3.12)  
1Restricted analysis on participants without any psychiatric disorders  
2Restricted analysis on participants with ApoE ε4 measurement and ApoE ε4 status was adjusted in the propensity score model  
3Analysis allows for time-varying treatment  
4Selective serotonin reuptake inhibitors  
5Serotonin and norepinephrine reuptake inhibitors  
6Atypical antidepressants  















Figure 2.2. Illustration of Matching Process  
 
Note: This figure is for illustrative purpose only. Participant information used for this 

























CHAPTER THREE. THE EFFECTS OF UNMEASURED SLEEP DISORDERS ON 
THE RELATIONSHIP BETWEEN ANTIDEPRESSANT USE AND THE RISK OF 
DEMENTIA  
 
3.1. Introduction  
In epidemiologic studies, causal effects of an exposure on an outcome are of 
interest. Causation can be inferred in an ideal randomized trial, because randomization 
will ensure the exchangeability between the exposed group and the unexposed group80. 
However, since randomization is often not feasible, we are left with observational data 
where the exposed group and the unexposed group are not always comparable to each 
other34. It is common in observational studies that confounding is controlled by statistical 
methods, but the potential uncontrolled confounding may still lead to distorted estimation 
of the association between exposure and outcome. It is generally expected that 
exchangeability and perfect adjustment of all confounders will not be true in 
observational studies.  
In Chapter Two, Inverse Probability Weighting methods were used to assess the 
average causal effects of antidepressants on the risk of dementia using National 
Alzheimer’s Coordinating Center (NACC) Uniform Data Set (UDS). A pseudo-cohort, in 
which the prognostic factors for receiving a certain type of treatment were balanced 
across groups, was constructed under the assumption that there was no unmeasured 
confounding given the observed data. The impacts of antidepressants on the risk of 
dementia were evaluated using the pseudo-cohort so that the causal effects could be 
inferred. Nevertheless, the assumption that there are no unmeasured confounders may not 




There are several reasons why the assumption of no unmeasured confounding 
may not be true. First, some hypothetical confounders for the association between 
antidepressant use and dementia, including socio-economic status and physical activities, 
are not measured in the UDS. Second, even for hypothetical confounders measured in the 
UDS, some of them are not usable for the purpose of this study. For example, information 
about sleep apnea, rapid-eye-movement behavior disorder (RBD), and insomnia is only 
collected for the UDS version 3, which was implemented in March 2015. UDS visits 
prior to the implementation of the UDS version 3 (September 2005-February 2015) did 
not collect this information. In other words, these variables suffer from heavy 
missingness.  
Based on our hypothesized causal model, an ideal observational study that 
evaluates the effects of antidepressants on the risk of dementia would include 
measurements for age, sex, race, education, socio-economic status, smoking, alcohol 
abuse, physical activities, traumatic brain injury (TBI), Parkinson’s disease, hypertension, 
type 2 diabetes, high cholesterol, stroke, cardiovascular disease (CVD), chronic pain, 
sleep disorders, depression status, any other psychiatric conditions except for depression 
(for example anxiety etc.), cognitive status, anti-anxiety medication use, and ApoE ε4 
allele status81,82 (see Figure 2.3). As mentioned previously, socio-economic status and 
physical activities are not measured in the UDS, and sleep disorder variables suffer from 
heavy missingness. Based on Figure 2.3, the minimal sufficient adjustment set includes 
baseline age, chronic pain, sleep disorders, depression status, Geriatric Depression Scale 
(GDS) score, any other psychiatric conditions except for depression (i.e. post-traumatic 




developmental neuropsychiatric disorder), standard CDR sum of boxed, and cognition. 
Unfortunately, sleep disorders could not be included in the analysis.  
Failing to adjust for sleep disorders in the analysis may lead to inaccurate effect 
estimates. For example, a series of studies have investigated the impact of sleep apnea on 
cognition, and it is believed that sleep apnea is associated with cognitive dysfunctions83-85. 
Similarly, studies suggest that Rapid Eye Movement Behavior Disorder (RBD) and 
insomnia are associated with impaired cognition75,86-88. On the other hand, sleep disorders 
are associated with antidepressant use. For example, SSRIs may cause insomnia89, and 
trazodone, which is a type of atypical antidepressant, is often used for treating insomnia90.  
In this study, the effects of sleep disorders as unmeasured confounders for the 
association between antidepressant use and the risk of dementia were investigated. The 
average causal effects of antidepressants on the risk of dementia adjusted for both 
measured and unmeasured confounders were assessed.  
 
3.2. Methods  
In Chapter Two, the effects of different classes of antidepressant were estimated 
assuming we controlled for all potential confounders. This assumption may not be valid 
due to the omission of sleep disorders. Hence, in this Chapter, 1) a bias factor formula for 
two binary unmeasured confounders is derived; 2) Monte Carlo Sampling is implemented 
to estimate the distribution of the bias factor for each class of antidepressant; 3) the 
effects of antidepressants on the risk of dementia are adjusted for both measured and 
unmeasured confounders are estimated. Table 3.1 summarizes the confounder 





3.2.1. Formula of Bias Factor  
For the purposes of this study, we limit our discussion to two binary unmeasured 
confounders. Let X be the indicator for use of a certain class of antidepressant, Z be a 
vector of controlled covariate values at baseline, 𝑈𝑈1  be the indicator for uncontrolled 
confounder 1, and 𝑈𝑈2 be the indicator for uncontrolled confounder 2. Let 𝐻𝐻𝐻𝐻𝑜𝑜𝑜𝑜𝑜𝑜 be the 
estimated observed hazard ratio for a certain class of antidepressant that is adjusted for 
the effects of the covariates in Z, but does not adjust for the effects of U. 𝐻𝐻𝐻𝐻𝑜𝑜𝑜𝑜𝑜𝑜 can be 
written as:  
𝐻𝐻𝐻𝐻𝑜𝑜𝑜𝑜𝑜𝑜 =
𝜆𝜆0(𝑡𝑡) · exp(𝛽𝛽(𝑋𝑋 = 1) + 𝛾𝛾𝒁𝒁)
𝜆𝜆0(𝑡𝑡) · exp(𝛽𝛽(𝑋𝑋 = 0) + 𝛾𝛾𝒁𝒁)
 
= exp(𝛽𝛽) 
Let 𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎  be the hypothetical hazard ratio for a certain class of antidepressant that 
adjusted for the effects of both Z and U. 𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎 is the target parameter of interest in this 
study, and it can be written as: 
𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎 =
𝜆𝜆0(𝑡𝑡) · exp(𝛽𝛽∗(𝑋𝑋 = 1) + 𝛾𝛾∗𝒁𝒁 + 𝜔𝜔𝑼𝑼))
𝜆𝜆0(𝑡𝑡) · exp(𝛽𝛽∗(𝑋𝑋 = 0) + 𝛾𝛾∗𝒁𝒁 + 𝜔𝜔𝑼𝑼))
 
= exp(𝛽𝛽∗) 
Let 𝑃𝑃𝑋𝑋,𝑈𝑈1,𝑈𝑈2 denote the proportion of subjects for the specific 𝑈𝑈1-𝑈𝑈2 stratum in group X=x. 
For example, 𝑃𝑃1,1,0 is the proportion of subjects who reported using a certain class of 
antidepressant X=1 and have condition 𝑈𝑈1but not 𝑈𝑈2.  
The change in the hazard for the control group due to 𝑈𝑈1  and 𝑈𝑈2 , denoted as 




1,𝑈𝑈2 = 0) , (𝑈𝑈1 = 0,𝑈𝑈2 = 1)  and (𝑈𝑈1 = 1,𝑈𝑈2 = 1)  in the control group using 𝑃𝑃0,0,0 , 
𝑃𝑃0,1,0, 𝑃𝑃0,0,1, 𝑃𝑃0,1,1 as weights. 𝐻𝐻𝐻𝐻𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐∗  can be written as:  
𝐻𝐻𝐻𝐻𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐∗ = � � exp(𝜔𝜔1𝑈𝑈1 + 𝜔𝜔2𝑈𝑈2)𝑃𝑃0,𝑈𝑈1,𝑈𝑈2
𝑈𝑈2𝑈𝑈1
 
= 𝑃𝑃0,0,0 + exp(𝜔𝜔1)𝑃𝑃0,1,0 + exp(𝜔𝜔2)𝑃𝑃0,0,1 + exp(𝜔𝜔1 + 𝜔𝜔2)𝑃𝑃0,1,1 
Similarly, the change in the hazard for a certain class of antidepressant due to 𝑈𝑈1 and 𝑈𝑈2, 
denoted as 𝐻𝐻𝐻𝐻𝑐𝑐𝑐𝑐𝑐𝑐∗ , can be written as:  
𝐻𝐻𝐻𝐻𝑐𝑐𝑐𝑐𝑐𝑐∗ = � � exp(𝜔𝜔1𝑈𝑈1 + 𝜔𝜔2𝑈𝑈2)𝑃𝑃1,𝑈𝑈1,𝑈𝑈2
𝑈𝑈2𝑈𝑈1
 
= 𝑃𝑃1,0,0 + exp(𝜔𝜔1)𝑃𝑃1,1,0 + exp(𝜔𝜔2)𝑃𝑃1,0,1 + exp(𝜔𝜔1 + 𝜔𝜔2)𝑃𝑃1,1,1 
where ∑𝑈𝑈 means sum over all values of U.  
Any difference between 𝐻𝐻𝐻𝐻𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐∗  and 𝐻𝐻𝐻𝐻𝑐𝑐𝑐𝑐𝑐𝑐∗  can only be due to the differences in 
the distributions of 𝑈𝑈1  and 𝑈𝑈2  between the treatment group and the control group. 
Therefore, the change in hazard due to differences in 𝑈𝑈1 and 𝑈𝑈2 between the treatment 





𝑃𝑃1,0,0 + exp(𝜔𝜔1)𝑃𝑃1,1,0 + exp(𝜔𝜔2)𝑃𝑃1,0,1 + exp(𝜔𝜔1 + 𝜔𝜔2)𝑃𝑃1,1,1
𝑃𝑃0,0,0 + exp(𝜔𝜔1)𝑃𝑃0,1,0 + exp(𝜔𝜔2)𝑃𝑃0,0,1 + exp(𝜔𝜔1 + 𝜔𝜔2)𝑃𝑃0,1,1
 
(Formula 1) 
Hence, the observed HR adjusted for 𝑈𝑈1 and 𝑈𝑈2, i.e. 𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎, can be estimated by dividing 











3.2.2. Monte Carlo Sampling  
In this study, four bias factors need to be estimated: SSRI users relative to 
controls, SNRI users relative to controls, AA users relative to controls, and TCA users 
relative to controls. Monte Carlo Sampling was performed to estimate the distribution of 
each bias factor.  
The prior distribution of the HR for sleep apnea was obtained from a large 
population-based retrospective matched-control cohort study using the Longitudinal 
Health Insurance Database 2005 in Taiwan91. The study cohort comprised 1414 subjects 
with sleep apnea and 7070 subjects without sleep apnea who were matched with the sleep 
apnea subjects on sex, age and index-year. A Cox Proportional Hazards regression model 
was performed to estimate the 5-year dementia-free survival rates after adjusting for 
potential confounders. The investigators concluded that subjects with sleep apnea have 
1.70 (95% CI: 1.26-2.31) times the hazard of developing dementia within 5 years of 
diagnosis compared to subjects without sleep apnea after adjusting for potential 
confounders.  
The prior distribution of the HR for RBD on the risk of dementia was obtained 
from a population-based cohort study investigating the impacts of RBD on the risk of 
MCI, dementia or Parkinson’s disease87. Subjects were randomly selected from the 70-89 
years old residents of Olmsted County, Minnesota, USA to participant in the Mayo Clinic 
Study of Aging. The study cohort consists of 44 subjects with probable RBD and 607 
subjects without probable RBD. A Cox Proportional Hazards regression model was 
performed to estimate the adjusted hazard ratio and the corresponding 95% confidence 




were followed prospectively for a median of 3.8 years. Subjects with probable RBD had 
2.2 (95% CI: 1.3-3.9) times the hazard of MCI/PD (no subject developed dementia by the 
end of the study) compared to subjects without probable RBD.  
The prior distributions for the prevalence of each sleep apnea-RBD stratum were 
obtained from the NACC UDS population. The sleep apnea and RBD variables are only 
available for UDS version 3, thus these two potential confounders could not be included 
into the main analysis in Chapter Two. However, we can still use the available 
information as the prior distributions for the prevalence of sleep apnea and the prevalence 
of RBD.  
Table 3.2 summarizes the prior distribution specification for each parameter used 
for estimating the empirical distributions of the 𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎. Normal distributions for the log 
hazard ratios 𝜔𝜔1 and 𝜔𝜔1  were used. Dirichlet distributions for the proportion for each 
sleep apnea-RBD stratum among the certain treatment group were used. Distributions for 
the observed estimated model coefficients were taken from the Main Analysis in Chapter 
Two to add random sampling errors into the Monte Carlo analysis.  
We drew 10,000 samples of 𝜔𝜔1 and 𝜔𝜔1 respectively from the specified Normal 
distributions, and 10,000 sets of samples of treatment prevalence across the sleep apnea-
RBD stratum. Under Formula 1, 10,000 bias factors were computed for each treatment 
group respectively. Furthermore, we drew 10,000 samples of 𝐻𝐻𝐻𝐻𝑜𝑜𝑜𝑜𝑜𝑜 for each treatment 
group respectively from the Normal distributions using the distributions for the observed 
estimated model coefficients. Thus, we were able to calculate 10,000 𝐻𝐻𝐻𝐻𝐵𝐵𝑎𝑎𝑎𝑎𝑎𝑎 for each 
class of antidepressant. The calculated 𝐻𝐻𝐻𝐻𝐵𝐵𝑎𝑎𝑎𝑎𝑎𝑎 formed an empirical distribution of 𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎 




shaped distributions (see Figure 3.1). The mean of each empirical distributions was 
computed as the point estimate of 𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎. The 2.5th and 97.5th percentiles were found as 
the lower confidence limit and upper confidence limit, respectively.  
 
3.3. Results  
In this study, sleep apnea and RBD were identified as the two sources of 
unmeasured confounding. The estimated mean of 𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎  and the 95% CI for each 
treatment group are displayed in Table 3.3 with a comparison of 𝐻𝐻𝐻𝐻𝑜𝑜𝑜𝑜𝑜𝑜 from the Main 
Analysis in Chapter Two.  
In Chapter Two, a weighted Cox Proportional Hazards regression model with 
antidepressant treatment as the only predictor in the model was performed. Subjects 
reported using SSRIs, SNRIs, AAs, and TCAs at the index-visit were estimated to have 
2.04 (1.69-2.48), 2.10 (1.33, 3.31), 1.46 (1.05, 2.03) and 1.58 (1.04, 2.41) times the 
hazard of developing dementia compared to subjects who did not report using any 
antidepressants at the index-visit, respectively. All estimates were significant at the 0.05 
level.  
In this Chapter, after adjusting for the unmeasured effects of sleep apnea and 
RBD, subjects who reported using SSRIs, SNRIs, AAs and TCAs at the index-visit were 
estimated to have 1.95 (1.59, 2.36), 1.85 (1.11, 2.91), 1.34 (0.93, 1.87) and 1.63 (1.04, 
2.43) times the hazard of developing dementia compared to subjects who did not report 
using any antidepressant use at index-visit, respectively. All estimates are still significant 




null for SSRI, SNRI and AA users, but the estimates adjusted for sleep apnea and RBD 
remained approximately the same for the TCA users (Figure 3.1).  
 
3.4. Discussion  
In this study, sleep apnea and RBD were identified as the two major sources of 
unmeasured confounding in our previous analyses of antidepressant use and dementia 
risk. The magnitude of bias caused by the effects of sleep apnea and RBD were estimated 
though Monte Carlo sampling. The hazard ratios adjusted for the effects of sleep apnea 
and RBD were computed by dividing the hazard ratios unadjusted for the effects of sleep 
apnea and RBD by the estimated magnitudes of bias.  
In the Main Analysis in Chapter Two, we ignored the effects of sleep apnea and 
RBD, thus the distribution of sleep apnea or RBD may not be comparable across 
treatment groups, hence the estimated effects of antidepressant on the risk of dementia 
may be distorted. We hypothesize that the results from the Monte Carlo analysis 
improved the estimates from Chapter Two towards the “true” direction by accounting for 
the effects introduced by sleep apnea and RBD.  
The hazard ratios adjusted for sleep apnea and RBD and the corresponding 95% 
confidence intervals were shifted toward the null for the SSRI, SNRI, and AA users, but 
the point estimate of the hazard ratio adjusted for sleep apnea and RBD for the TCA users 
is slightly shifted away from the null (the 95% confidence interval remained 
approximately the same). The estimation of the effect of TCA on the risk of dementia 
was not sensitive to the omission of sleep apnea and RBD. In other words, sleep apnea 




This study has some limitations. First, prior distribution specifications for 
parameters are based on a single study for each parameter. While the studies were 
population-based, the populations studied may not be comparable to the NACC UDS 
population. An improvement could be obtaining prior distribution parameters by 
conducting meta-analyses. Second, proportions for each sleep apnea-RBD stratum across 
the treatment groups were obtained from the UDS version 3, which was initiated after 
2015. Compared with the study population in this dissertation, participants in the UDS v3 
subgroup were in general younger, had higher proportions for psychiatric disorders 
(including depression and any other types) and had higher proportions of MCI diagnosis 
at baseline. Thus, this subgroup was not a representative sample of the study population 
in this research. Finally, this study was restricted to two binary unmeasured confounders, 
hence insomnia is not discussed in this study. However, insomnia may be an important 
confounder for the association between antidepressant use and risk of dementia and 
should be addressed.  
 
3.5. Conclusion  
In this Chapter, the effects of sleep apnea and RBD as uncontrolled confounders 
between the association between antidepressant use and the risk of dementia were 
investigated. A bias factor formula for two binary unmeasured confounders was derived. 
Monte Carlo analysis was implemented to estimate the distribution of bias factor for each 
class of antidepressant. The effects of antidepressants on the risk of dementia adjusted for 
both measured and unmeasured confounders were estimated. Sleep apnea and RBD bias 




Sleep apnea and RBD may not be a confounder on the pathway between TCA use and 
developing dementia. For future studies, meta-analysis could be conducted to obtain the 
prior distributions for parameters. Additionally, the effects of insomnia and other types of 
sleeping disorders can be investigated. 





Table 3.1. Confounder Adjustment Status  











Demographics  Age  √ √ √ √ 
Sex  √    
Race  √    
Education  √    
SES1      
Life Styles  Smoking  √    
Alcohol abuse √    





TBI2  √    
Parkinson  √    
Hypertension  √    
Type 2 diabetes  √    
High cholesterol  √    
Stroke  √    
CVD3  √    
Chronic pains √ √ √ √ 
Sleep disorders   √  √ 
Depression  √ √ √ √ 
GDS score4 √ √ √ √ 
Other psychiatric 
disorders  
√ √ √ √ 
CDR sum of boxes √ √ √ √ 
Cognition status √ √ √ √ 
Anti-anxiety 
medications  
√    
Genetics  ApoE ε4 status √  √  
1Socio-economic Status  
2Traumatic Brain Injury  
3Cardiovascular Disease  





Table 3.2. Parameter Prior Distribution Specifications  
 𝛃𝛃𝒐𝒐𝒐𝒐𝒐𝒐5 𝝎𝝎𝟏𝟏6 𝝎𝝎𝟐𝟐7 𝑷𝑷𝑿𝑿,𝑼𝑼𝟏𝟏,𝑼𝑼𝟐𝟐
8 
Control  -- 
N (0.53, 0.15) N (0.79, 0.28) 
Dirichlet (1926,350,34,17) 
SSRI1 N9 (0.71, 0.10) Dirichlet (331, 87, 6, 7) 
SNRI2 N (0.74, 0.23) Dirichlet (71, 32, 0, 5) 
AA3 N (0.38, 0.17) Dirichlet (135, 41, 3, 6) 
TCA4  N (0.46, 0.21) Dirichlet (40, 8, 1, 0) 
1Selective serotonin reuptake inhibitors  
2Serotonin and norepinephrine reuptake inhibitors  
3Atypical antidepressants  
4Tri-cyclic antidepressants  
5Observed beta coefficient from the Main Analysis in Chapter Two  
6Log hazard ratio for sleep apnea from literature  
7Log hazard ratio for RBD from literature  
8Prevalence of each sleep apnea-RBD stratum in the UDS for a certain treatment group  






Table 3.3. Estimated Bias-factor Adjusted and Observed Hazard Ratios for Dementia 
 𝑯𝑯𝑯𝑯𝒐𝒐𝒐𝒐𝒐𝒐 𝑯𝑯𝑯𝑯𝒂𝒂𝒂𝒂𝒂𝒂 
SSRI1  2.04 (1.69, 2.48) 1.95 (1.59, 2.36) 
SNRI2 2.10 (1.33, 3.31) 1.85 (1.11, 2.91) 
AA3 1.46 (1.05, 2.03) 1.34 (0.93, 1.87) 
TCA4  1.58 (1.04, 2.41) 1.63 (1.04, 2.43)  
1Selective serotonin reuptake inhibitors  
2Serotonin and norepinephrine reuptake inhibitors  
3Atypical antidepressants  













CHAPTER FOUR. RE-ESTIMATING THE EFFECTS OF ANTIDEPRESSANT USE 
ON THE RISK OF DEMENTIA USING MULTI-STATE MARKOV CHAIN 
 
4.1. Introduction  
The current recommendation for treating major depressive disorders is to use 
antidepressants over prolonged periods to relieve symptoms and prevent further episodes 
of depression92,93. The initial selection of an antidepressant medication is primarily 
dependent on the anticipated side effects, the safety or tolerability of these side effects for 
the patient, the pharmacological properties of the medication, and other factors such as 
patient’s response to previous treatment, patient preference, insurance formulary, and 
cost94. However, psychiatrists may suggest changing the treatment regimen if poor 
efficacy or intolerance is observed93. Additionally, patients may discontinue 
antidepressant treatment for various reasons95.  
In previous chapters, the effects of antidepressant medication on the hazard of 
developing dementia were assessed assuming participants adhere to the initial treatment 
assignment. To briefly summarize, antidepressant use was fixed at the index-visit and 
intent-to-treat analysis was used. A Cox Proportional Hazards regression model with 
Inverse Probability Weighting was then performed to assess the hazard for developing 
dementia.  
There are important assumptions made in the previous Cox regression analyses. 
First, participants were assumed to stick with the treatment assignment at the index visit 
until a certain event of interest occurs. Second, the hazards for developing dementia were 
assumed to be proportional over time. Third, participants were assumed to make only one 




the potential transitions among cognitive states prior to the occurrence of a certain event 
were ignored. Furthermore, we made the assumption that participants could not recover 
from mild impairment.  
In practice, participants in the National Alzheimer’s Coordinating Center are 
assessed annually. Cognitive status, medication use, physical and neurological 
examinations, and medical history are recorded at each assessment. Participants may 
switch or discontinue antidepressant treatments. Participants’ characteristics (e.g., 
comorbidities, medication use, demographic information, etc.) may also change over time. 
Such changes may lead to time-varying hazards for developing dementia. In addition, 
participants may transition among different cognitive stages, such as normal cognition 
and mild cognitive impairment (MCI), before developing dementia. Participants may die 
from other causes, such as cancer, cardiovascular diseases, etc., before developing 
dementia, and such deaths will prevent participants from developing dementia. In the 
situation where the hazard of a certain health outcome is varying over time and the 
outcome may occur more than once, Markov models will be particularly useful96.  
In this study, we assessed the association between each class of antidepressant 
and the probability of dementia while accounting for the potential time-varying risks for 
dementia and the potential transitions among different cognitive stages before finally 
developing dementia. To achieve this goal, multi-state Markov models based on 





4.2. Methods  
4.2.1. Data Source and Subjects  
Subjects of this study are those who participated in the annual assessment at the 
National Alzheimer’s Coordinating Center (NACC), as known as the Uniform Data Set 
(UDS)97. The detailed description of the NACC UDS can be found in Chapter Two. 
Briefly, the NACC UDS was collected by trained clinicians and clinical practitioners 
from participants and their co-participants during in-person office visits following a 
standard data collection protocol. The UDS includes subjects with various levels of 
cognitive status: dementia caused by different reasons, different levels of cognitive 
impairment, and intact cognition61. As of September 2018, among all the UDS subjects, 
35.1% were diagnosed with normal cognition, 4.3% were impaired but not MCI, 17.2% 
were diagnosed with MCI, and 43.4% had been diagnosed with dementia.  
The following exclusion criteria were implemented for the purpose of this study. 
After applying these exclusion criteria, 11,939 subjects remained in the study (Figure 4.1). 
1) prevalent dementia patients at the initial UDS visit;  
2) prevalent antidepressant users at the initial UDS visit;  
3) participants with only one UDS visit;  
4) participants who were younger than 65-years-old at the initial UDS visit;  
5) MAOI users or combination users at the index-visit.  
 
4.2.2. Measurements  
The methods used for measuring antidepressant use, cognitive status and other 




participants were asked about their medication use within two-week window prior to the 
current UDS visit. The four classes of antidepressants identified are selective serotonin 
reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), 
tri-cyclic antidepressants (TCAs) and atypical antidepressants (AAs).  Based on 
clinicians’ assessments, cognitive status is classified into four levels: normal cognition, 
mild cognitive impairment (MCI), impaired but not MCI, and dementia. A series of 
cognitive or behavioral symptoms should be met for patients to be defined as any of the 
four levels of cognitive status61. Based on the DAG constructed in Chapter Two, 
covariates for adjustment included age, chronic pain, depression status, GDS score, 
psychiatric conditions other than depression, standard CDR sum of boxes, and the 
cognitive status. ApoE ε4 status was not included in the models since the results from the 
Sensitivity Analysis Two in Chapter Two indicated that ApoE ε4 status is not a 
confounder on the pathway between antidepressant use and dementia development. 
Subjects’ treatment values, covariates values and cognitive status were assessed at every 
UDS visit.  
 
4.2.3. Statistical Analysis  
To evaluate the effects of different classes of antidepressants on the risk of 
dementia while accounting for the time-varying treatment and time-varying confounders, 
a multi-state Markov chain was implemented. One limitation of the estimations in 
Chapter Two was that treatment assignment and confounders for adjustment were fixed at 
the treatment UDS visit and baseline UDS visit respectively, regardless of the treatment 




conducted a sensitivity analysis using time-varying treatment, which supported our main 
results, we could not accommodate time-varying confounders. This issue can be 
accommodated by the multi-state Markov chain. Additionally, competing risks for the 
main outcome of interest, in this case death before dementia, can also be addressed by 
this approach, along with back transitions. 
A multi-state Markov chain with three transient states (normal cognition, 
impaired but not MCI, and MCI) and two absorbing states (dementia and death prior to 
dementia) was constructed to estimate the probabilities of moving from a prior state to a 
current state. Subjects may move back and forth between any two of the transient states 
in a transition cycle, but once a subject enters an absorbing state, the subject will never 
exit (Figure 4.2). Although participants may die after developing dementia, those 
transitions were not of interest in this study. A participant’s follow-up ended with entry 
into an absorbing state or their last active UDS visit. A subject-specific shared random 
effect, which was assumed to have normal distribution, was included in the models to 
account for the within-subject correlation98.  
Specifically, a series of three polytomous logistic regression models were built to 
model log-odds of the one-step transitions between any two transient states or the one-
step transitions between a transient state and an absorbing state, conditioned on the prior 
(transient) state:  
logit �𝑷𝑷𝒑𝒑,𝒄𝒄(𝑡𝑡𝑡𝑡𝐵𝐵𝑡𝑡𝐵𝐵𝐵𝐵𝑡𝑡𝐵𝐵𝑡𝑡𝑡𝑡 = 1|𝒙𝒙𝑖𝑖, 𝒛𝒛𝑖𝑖,𝒖𝒖𝑖𝑖)� = 𝜶𝜶𝒑𝒑,𝒄𝒄 + 𝜷𝜷𝑝𝑝,𝑐𝑐𝑇𝑇 𝒙𝒙𝑖𝑖 + 𝜸𝜸𝑝𝑝,𝑐𝑐𝑇𝑇 𝒛𝒛𝑖𝑖 + 𝒖𝒖𝑖𝑖 
Here, x is a vector of indicators for treatment; z is a vector of covariates for adjustment, 
and u is the subject-specific shared random effect. The subscript i refers to subject i, p 




normal cognition and the current state is MCI, 𝑷𝑷𝒑𝒑,𝒄𝒄 represents the probability of transition 
from normal cognition to MCI versus remaining in normal cognition, given values of x, z 
and u. All transitions are assumed to occur on the visit date. Any transitions among the 
transient states between the visits, which are not observed, are ignored.  
To evaluate the predicted time for transition from one particular state to another, a 
Markov cohort simulation analysis was conducted using the estimated transition 
probabilities based on the fitted models for the one-step transitions. Times spent on 
transitions from baseline normal cognition to dementia and transitions from baseline MCI 
to dementia were estimated for each class of antidepressant assuming different baseline 
ages and different baseline depression statuses, while controlling for the effects of other 
covariates.  
For the purpose of this study, transitions from and to “impaired but not MCI” 
were included in the model, but these results are of limited interest since the “impaired 
not MCI” category is quite heterogeneous. A diagnosis of “impaired but not MCI” 
denotes clinical impairment on cognition but does not meet criteria for MCI or dementia. 
The underlying causes of this impairment are unknown, and may include medical 
conditions, psychiatric conditions, and medication-induced cognitive dysfunction. Thus, 
we included this diagnosis as a state in order not to exclude data from these visits. 
However, it is not clear to what type of person these results would generalize. Therefore, 
these results are reported but not discussed in detail. All analyses were performed using 





4.3. Results  
Participants’ had a median of four annual assessments, with an interquartile range 
of 2 to 7 visits. The median days between assessments was 378 days, with an interquartile 
range of 358 to 427 days. For purposes of describing the sample, participant 
characteristics were fixed at the initial UDS visit, hence no participants were yet taking 
antidepressants (Table 4.1). At the initial visit, the average age for this cohort of 
participants was 76-years-old, and more than one-third (36.8%) of these participants 
reported using pain medications. Additionally, about one fifth of the participants had at 
least one psychiatric disorder (16.6% had depression and 4.1% had any other psychiatric 
disorder except for depression). Most of the participants had normal cognition at entry 
(63.9%), while 30.1% of the participants had MCI.  
During the study period, 1741 participants (14.6%) made at least one transition 
from normal cognition to MCI, 235 participants (2.0%) transitioned from normal 
cognition to dementia, and 773 participants (6.5%) died with normal cognition. 
Additionally, 1897 participants (15.9%) transitioned from MCI to dementia, and 534 
participants (4.5%) died with MCI. Detailed one-step transition distributions are 
summarized in Table 4.2. In general, participants were most likely to remain in the 
transient state where they were previously observed. Transitions to dementia were most 
likely to occur from MCI. Back transitions from impaired but not MCI to normal and 
from MCI to normal were relatively common.  
Transitions of interest are marked bold in Table 4.3. For transitions from normal 
cognition to MCI, SSRIs, SNRIs and TCAs were estimated to increase the probability of 




normal cognition directly to dementia, SSRIs, SNRIs and AAs were estimated to increase 
the probability of the transition, but TCAs are associated with a significantly reduced 
probability. For transitions from MCI to dementia, SSRIs, AAs and TCAs are associated 
with increased probability for transition, but SNRIs is associated with a reduced 
probability for transition. The estimate for SSRI is significant. Finally, for transitions 
from MCI back to normal cognition, all types of antidepressant are associated with 
reduced odds, indicating that antidepressant use may prevent recovering from MCI to 
normal. Figure 4.3 displays the adjusted odds ratios and the corresponding 95% 
confidence intervals for transitions of interest for each class of antidepressant.  
Markov cohort simulation analysis was conducted to evaluate the transition time 
from one particular state to another. Times spent on transitions from normal cognition to 
dementia and transitions from MCI to dementia for each class of antidepressant were of 
the primary interest. Times were estimated by assuming different baseline ages and 
different baseline depression status (Figure 4.4). In general, it takes longer time for 
transitions from normal cognition to dementia compared to transitions from MCI to 
dementia, regardless of the antidepressant use, baseline age or baseline depression status.  
For transitions from normal cognition to dementia, different antidepressant users 
would spend different lengths of time in the normal state before moving to dementia. 
Participants in control group need the longest time to make the transition, while SNRI 
users need the shortest time to make the transition, assuming fixed baseline ages and 
depression status. SSRI users, AA users and TCA users need similar times for the 
transition. Baseline age and baseline depression status will further influence the times for 




assuming fixed treatment and fixed baseline depression status. Participants with 
depression at baseline will result in shorter transition times compared to participants 
without depression at baseline assuming fixed treatment and fixed baseline age.  
For transitions from MCI to dementia, participants in comparison group would 
spend the longest time in the MCI state before moving to dementia while all the other 
antidepressant users will move to dementia quicker than the controls assuming fixed 
baseline age and baseline depression status. The differences in transition times among 
different antidepressant classes are not obvious for transitions from MCI state as they are 
for transitions from normal state. Increased baseline age would reduce the time spent in 
the normal state assuming fixed treatment and fixed baseline depression status. 
Participants with depression at baseline would have reduced transition times compared to 
participants without depression at baseline assuming fixed treatment and fixed baseline 
age.  
 
4.4. Discussion  
In this project, a multi-state Markov chain was implemented to evaluate the 
effects of antidepressants on the risk of dementia while accounting for the time-varying 
treatment and time-varying confounders. First, a series of three multinomial logistic 
regression models were built to model log-odds of the one-step transitions between any 
two transient states or the one-step transitions between a transient state and an absorbing 
state, conditioned on the prior (transient) state. Second, a Markov cohort simulation 
analysis was conducted using the estimated transition probabilities based on the fitted 




The estimated effects of different classes of antidepressant on the one-step 
transition suggested that in general antidepressant use is associated with increased odds 
of moving towards the next worse cognitive status, and antidepressant use is also 
associated with reduced odds of moving back to the previous healthier cognitive status. In 
other words, antidepressant use was estimated to be associated with harmful impacts on 
cognition. The estimated transition times associated with each class of antidepressant 
illustrates the results obtained from the models. Antidepressant users would move quicker 
from either normal state or MCI state to demented state compared to the non-users.  
As discussed in Chapter Two, there are several explanations for the potential 
mechanisms of the effects of antidepressants on dementia. For example, an animal study 
has found that SSRI treatment is associated with imbalance zinc levels, which may lead 
to neurofibrillary tangles, which is a marker of Alzheimer’s disease and cognitive 
impairment73. Additionally, SNRI may increase user’s blood pressure64,70,  and 
hypertension is a risk factor for vascular dementia and Alzheimer’s dementia71. However, 
the association between antidepressant use and dementia may still be due to reverse 
causality78, where preclinical neurodegenerative disease causes depression, which causes 
antidepressant initiation, which induces the association between antidepressant use and 
dementia.  
Age is known to be a strong risk factor for cognitive decline99. In this study, the 
effects of antidepressants on transition times were impacted by different baseline ages. It 
would take less time for older antidepressant users to move to dementia compared with 
younger antidepressant users across all antidepressant classes. There have been studies 




example, compared with the younger antidepressant users, concerns for the 
antidepressant users among the elderly included the differences in disposition, altered 
sensitivity to side effects, potential drug-drug interactions, decreased homeostatic reserve 
and possibly decreased sensitivity to antidepressant efficiency102.  
The effects of antidepressants on transition times would also be influenced by 
different baseline depression status. Antidepressant users who reported depression at 
baseline would move to dementia faster than antidepressant users who did not report 
depression at baseline across all antidepressant classes. Studies have concluded that 
depression is a risk factor for cognitive declines81,82,103,104. However, we cannot rule out 
the possibility that depression is merely an early manifestation, rather than a predictor, of 
Alzheimer’s disease82,105.  
The cognitive status at the “from-state” may have impacted on the effects of 
antidepressant on the risk of dementia. The effects of antidepressant on transition times 
differ among different classes for participants in the normal state, but such differences 
were minimized for participants in the MCI state, although a clear difference between 
non-users and antidepressant users remained. We do note that the SSRI group, which was 
associated with increased odds of transition from normal to MCI or dementia, and from 
MCI to dementia, is associated with the shortest times to dementia from the normal state.  
There are several advantages for this study. First, our analysis allows for time-
varying treatment and time-varying confounders, hence we were able to address the 
potential changes of treatment regimen or participants’ characteristics over time. Second, 
a subsequent benefit of the incorporation of time-varying treatment and confounders is 




our study permits participants to transition among different cognitive stages before 
developing dementia, which is usually true in practice.  
There are some limitations for this study. First, all transitions are assumed to 
occur on the visit date, and any transitions among the transient states between the visits 
are ignored. Second, we cannot rule out the possibility of reverse causality, where 
antidepressant use is actually induced by depression as a comorbidity of preclinical 
neurodegeneration, rather than being a predictor of cognitive decline78. Third, we need to 
be aware that sleep disorders were not adjusted in the models due to the fact that the 
variables associated with sleep disorders were not properly measured for the purpose of 
this study.  
 
4.5. Conclusion  
In this study, we assessed the association between each class of antidepressant 
and the probability of dementia while accounting for the time-varying risks for dementia 
and the potential transitions among different cognitive stages before finally developing 
dementia. Multi-state Markov models based on multinomial logistic regression were 
constructed to model log-odds of the one-step transitions between any two transient states 
or the one-step transitions between a transient state and an absorbing state, conditioned 
on the prior (transient) state. A Markov cohort simulation analysis was conducted to 
evaluate the predicted time for transition from one particular state to another using the 





We found that in general antidepressant use is associated with increased odds of 
moving towards the next worse cognitive status, and antidepressant use is also associated 
with reduced odds of moving back to the previous healthier cognitive status. In addition, 
it took less time for older antidepressant users to move to dementia compared with 
youngers antidepressant users across all antidepressant classes. Finally, antidepressant 
users who reported depression at baseline would move to dementia faster than 
antidepressant users who did not report depression at baseline across all antidepressant 
classes.  
There are several directions for future studies. First, more accurate measurement 
on transition times should be implemented. Second, in studies with longer follow-up, 
reverse causality can be tested by excluding incident cases within the first pre-determined 
number of years of treatment. Finally, the potential confounding effects of sleep disorders 




Table 4.1. Summary of Subject Characteristics at the Initial Visit (N=11,939)  
Variable  All subjects 
Age (year) 76.0 ± 7.2 
Pain meds 4397 (36.8%) 
Depression  1979 (16.6%) 
GDS score1  1 (0, 2) 
Any other psychiatric disorders 483 (4.1%) 
CDR2 0 (0, 0.5)  
Cognitive status  
     Normal  
     MCI3 





Number of assessments  4 (2, 7) 
Days between assessments  378 (358, 427) 
Note: Mean ± S.D. are reported for normally-distributed continuous variables. Median 
(Q1, Q3) are reported for non-normally-distributed variables. Frequency (%) are 
reported for categorical variables. 
1Geriatric Depression Scale score  
2Standard CDR sum of boxes 





Table 4.2. One-step Transition Matrix (N=11,939) 
Prior Current  Normal MCI Impaired Dementia Death 
Normal 29000 (88.7) 1903 (5.8) 785 (2.4) 242 (0.7) 773 (2.4) 
MCI1 1016 (9.1) 7134 (64.2) 479 (4.3) 1941 (17.5) 534 (4.8) 
Impaired2 619 (22.3) 572 (20.6) 1348 (59.2) 133 (4.8) 104 (3.7) 
1Mild Cognitive Impairment  








Table 4.3. Adjusted Odds Ratios for Transitions among States  
new Prior Current Normal MCI5 Impaired6 Dementia Death 
SSRI1 
Normal -- 1.25 (0.89, 1.75)  1.42 (0.94, 2.15)  1.23 (0.57, 2.65)  1.27 (0.77, 2.11)  
MCI 0.64 (0.39, 1.05)  -- 0.69 (0.38, 1.26)  1.70 (1.28, 2.26)  1.70 (1.08, 2.67)  
Impaired 0.83 (0.48, 1.45)  0.53 (0.28, 0.97)  -- 0.52 (0.22, 1.23)  0.88 (0.36, 2.12)  
SNRI2 
Normal -- 1.60 (0.87, 2.94)  0.24 (0.03, 2.28)  1.97 (0.44, 8.79)  2.96 (1.25, 6.97)  
MCI 0.37 (0.11, 1.21) -- 1.26 (0.51, 3.09)  0.57 (0.27, 1.19)  0.87 (0.32, 2.37) 
Impaired 0.68 (0.15, 3.02)  0.49 (0.10, 2.35)  -- 0.45 (0.09, 2.25)  0.20 (0.06, 0.63)  
AA3 
Normal -- 0.71 (0.40, 1.28)  1.23 (0.63, 2.42)  1.06 (0.33, 3.40)  1.45 (0.78, 2.70)  
MCI 0.41 (0.15, 1.16)  -- 1.39 (0.60, 3.21)  1.18 (0.68, 2.04)  1.04 (0.52, 2.10)  
Impaired 0.65 (0.13, 3.19)  2.06 (0.64, 6.66)  -- 5.12 (1.26, 20.72)  4.28 (0.99, 18.58)  
TCA4 Normal -- 1.23 (0.59, 3.67)  1.46 (0.58, 3.67)  0.16 (0.11, 0.24)  0.93 (0.29, 3.00)  
MCI 0.57 (0.14, 2.32)  -- 0.08 (0.05, 0.14)  1.22 (0.51, 2.90)  0.91 (0.24, 3.42)  
Impaired 0.45 (0.02, 8.75)  0.41 (0.02, 7.51)  -- 2.69 (0.17, 43.28)  4.36 (0.59, 32.30) 
Note: transitions of interest are marked bold  
1Selective serotonin reuptake inhibitors 
2Serotonin and norepinephrine reuptake inhibitors 
3Atypical antidepressants 
4Tri-cyclic antidepressants  
5Mild Cognitive Impairment  
































CHAPTER FIVE. CONCLUSION 
5.1. Study Summary  
Given the public health significances of dementia and antidepressant use among 
the elderly, it is important to understand the relationship between antidepressant use and 
dementia development in this special population. The purpose of this research is to 
investigate the effects of different classes of antidepressant medications on the risk of 
dementia using causal inference strategies using data obtained from the National 
Alzheimer’s Coordinating Center (NACC) Uniform Data Set (UDS).  
In Chapter Two, a new users design retrospective cohort study was conducted to 
evaluate the causal effects of different classes of antidepressant on the risk of dementia 
by performing a Marginal Structural Cox Proportional Hazard Regression Model with an 
Inverse Probability Weighting estimator. Significant causal effects of SSRIs, SNRIs, AAs 
and TCAs on the risk of dementia were observed at the 0.05 significance level. In general, 
the estimates were not sensitive to confounding by indication of psychiatric disorders, 
genetic risk due to ApoE ε4 status, or treatment regime changes in later visits.  
In Chapter Three, the impacts of sleep apnea and rapid-eye-movement behavior 
disorder (RBD) as unmeasured confounders were assessed. Unmeasured confounding is a 
threat to the validity of causal inference methods. In evaluating the effects of anti-
depressants, it is important to consider how common comorbidities of depression may 
affect both the exposure to anti-depressants and the onset of cognitive impairment. A bias 
factor formula for two binary unmeasured confounders was derived in order to account 
for these variables. Monte Carlo analysis was implemented to estimate the distribution of 




of dementia adjusted for both measured and unmeasured confounders were estimated. 
Sleep apnea and RBD attenuated the effect estimates toward the null for SSRI, SNRI and 
AA on the risk of dementia. Sleep apnea and RBD may not be confounders between TCA 
use and dementia risk.  
In Chapter Four, a multi-state Markov chain with three transient states (normal 
cognition, impaired but not MCI, and MCI) and two absorbing states (dementia and death 
prior to dementia) was built to account for the treatment changes over time and time-
varying covariates. A series of polytomous logistic regression models were constructed to 
model the log-odds of transitions between any two transient states and transitions 
between a transient state and an absorbing state. A Markov cohort simulation analysis 
was conducted using the estimated transition probabilities from the estimated log-odds 
from the model results. In general, antidepressant use was estimated to be associated with 
harmful impacts on cognition. The estimated transition times for each class of 
antidepressant confirms the results obtained from the models. Antidepressant users would 
move quicker from either normal state or MCI state to demented state compared to the 
controls.  
 
5.2. Strengths and Limitations  
A major strength of this research is that we were able to simulate a “pseudo 
randomized study” with observational data following the intent-to-treatment principles, 
thus the causal effects of different classes of antidepressant could be estimated. 
Additionally, the potential uncontrolled confounding effects of sleep disorders were 




for several limitations that previous studies in the way that the marginal effects of 
antidepressant on the risk of dementia were estimated, rather than the conditional effects.  
Another strength of this research is that the time-varying treatment and time-
varying confounders were addressed by implementing a multi-state Markov chain, hence 
we were able to address the potential changes of treatment regimen or participants’ 
characteristics over time. In other words, the time-varying hazards for developing 
dementia were investigated in this research.  
However, one subsequent limitation is that the multi-state Markov chain was only 
able to estimate the conditional effects of antidepressants, thus we cannot conclude causal 
relationship between any class of the antidepressant under investigation which potentially 
changes over time and the risk of dementia. Moreover, to use multi-state Markov chain, 
we need to assume that all transitions occurred on the visit date, and any transitions 
among the transient states between the visits were ignored.  
Another limitation of this research is that we could not rule out the possibility of 
reverse causality, where antidepressant use is actually induced by depression as a 
comorbidity of preclinical neurodegeneration, rather than being a predictor of cognitive 
declines78. If the reverse causality is true, then the association we observed between 
antidepressant use and dementia may not be used for causal inference.  
 
5.3. Future Research  
There are several directions for future research suggested by the studies in this 
dissertation. First, we did not explore the possibility of causal inference in multi-state 




study. For example, the Inverse Probability Weighting or G-computation could be 
incorporated into the models to estimate the marginal effects of the treatment of interest. 
Second, the possibility of reverse causality should be checked. In this study, the follow-
up time was not long enough to assess the possibility of reverse causality, however, for 
studies with decades of follow-up, incident cases that arise in the first pre-determined 
number of years of treatment can be excluded to test the reverse causality hypothesis79. 
Finally, the medication measurement is not accurate in the UDS. In future studies, better 
measurements are expected. For example, during the UDS visit, participants were only 
asked if they were using any medication within two weeks before the current visit. Thus, 
details about the doses or indications associated with the reported medications were not 
available. Besides better measurements on the exposure, more accurate measurements on 
the timings of cognitive transition are needed to better estimate the impacts of some 
certain exposure on cognitive declines, and measurements on risk factors such as physical 
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